<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36791116</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>12</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>2</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>STIMULATE-ICP: A pragmatic, multi-centre, cluster randomised trial of an integrated care pathway with a nested, Phase III, open label, adaptive platform randomised drug trial in individuals with Long COVID: A structured protocol.</ArticleTitle><Pagination><StartPage>e0272472</StartPage><MedlinePgn>e0272472</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0272472</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0272472</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Long COVID (LC), the persistent symptoms &#x2265;12 weeks following acute COVID-19, presents major threats to individual and public health across countries, affecting over 1.5 million people in the UK alone. Evidence-based interventions are urgently required and an integrated care pathway approach in pragmatic trials, which include investigations, treatments and rehabilitation for LC, could provide scalable and generalisable solutions at pace.</AbstractText><AbstractText Label="METHODS AND ANALYSIS">This is a pragmatic, multi-centre, cluster-randomised clinical trial of two components of an integrated care pathway (Coverscan&#x2122;, a multi-organ MRI, and Living with COVID Recovery&#x2122;, a digitally enabled rehabilitation platform) with a nested, Phase III, open label, platform randomised drug trial in individuals with LC. Cluster randomisation is at level of primary care networks so that integrated care pathway interventions are delivered as "standard of care" in that area. The drug trial randomisation is at individual level and initial arms are rivaroxaban, colchicine, famotidine/loratadine, compared with no drugs, with potential to add in further drug arms. The trial is being carried out in 6-10 LC clinics in the UK and is evaluating the effectiveness of a pathway of care for adults with LC in reducing fatigue and other physical, psychological and functional outcomes at 3 months. The trial also includes an economic evaluation which will be described separately.</AbstractText><AbstractText Label="ETHICS AND DISSEMINATION">The protocol was reviewed by South Central-Berkshire Research Ethics Committee (reference: 21/SC/0416). All participating sites obtained local approvals prior to recruitment. Coverscan&#x2122; has UK certification (UKCA 752965). All participants will provide written consent to take part in the trial. The first participant was recruited in July 2022 and interim/final results will be disseminated in 2023, in a plan co-developed with public and patient representatives. The results will be presented at national and international conferences, published in peer reviewed medical journals, and shared via media (mainstream and social) and patient support organisations.</AbstractText><AbstractText Label="TRIAL REGISTRATION NUMBER">ISRCTN10665760.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2023 Forshaw et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Forshaw</LastName><ForeName>Denise</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Lancashire Clinical Trials Unit, University of Central Lancashire, Preston, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wall</LastName><ForeName>Emma C</ForeName><Initials>EC</Initials><Identifier Source="ORCID">0000-0003-2732-4497</Identifier><AffiliationInfo><Affiliation>Francis Crick Institute, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infection and Immunity, University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prescott</LastName><ForeName>Gordon</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-9156-2361</Identifier><AffiliationInfo><Affiliation>Lancashire Clinical Trials Unit, University of Central Lancashire, Preston, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dehbi</LastName><ForeName>Hakim-Moulay</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Comprehensive Clinical Trials Unit, University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Angela</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2047-0352</Identifier><AffiliationInfo><Affiliation>Department of Physiotherapy, Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Attree</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>STIMULATE-ICP PPI Team.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hismeh</LastName><ForeName>Lyth</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>STIMULATE-ICP PPI Team.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strain</LastName><ForeName>William D</ForeName><Initials>WD</Initials><AffiliationInfo><Affiliation>University of Exeter Medical School, Exeter, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Academic Department of Healthcare for Older People, Royal Devon and Exeter NHS Foundation Trust, Exeter, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crooks</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Academic Respiratory Medicine, Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hull York Medical School, Institute of Clinical and Applied Health Research, University of Hull, Hull, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watkins</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Lancashire Clinical Trials Unit, University of Central Lancashire, Preston, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robson</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Living With, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banerjee</LastName><ForeName>Rajarshi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Perspectum, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lorgelly</LastName><ForeName>Paula</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>School of Population Health, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Applied Health Research, University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heightman</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, University College London Hospitals NHS Trust, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHS England, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banerjee</LastName><ForeName>Amitava</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8741-3411</Identifier><AffiliationInfo><Affiliation>Institute of Health Informatics, University College London, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Barts Health NHS Trust, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, University College London Hospitals NHS Trust, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>STIMULATE-ICP trial team</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ISRCTN</DataBankName><AccessionNumberList><AccessionNumber>ISRCTN10665760</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>COV-LT2-0043</GrantID><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019033" MajorTopicYN="Y">Delivery of Health Care, Integrated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017326" MajorTopicYN="N">Clinical Trials, Phase III as Topic</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>We have read the journal&#x2019;s policy and the authors of this manuscript have the following competing interests: WDS holds research grants from Bayer, Novo Nordisk and Novartis and has received speaker honoraria from AstraZeneca, Bayer, Bristol-Myers Squibb, Merck, Napp, Novartis, Novo Nordisk and Takeda, outside the submitted work. WDS is supported by the NIHR Exeter Clinical Research Facility and the NIHR Collaboration for Leadership in Applied Health Research and Care (CLAHRC) for the South-West Peninsula. MGC has received honoraria, fees for advisory boards, and non-financial support from AstraZeneca, BI, Chiesi, GSK, Novartis, and Pfizer and grants from AstraZeneca, BI, Chiesi, and Pfizer. CR is director of Living With, which developed Living With COVID RecoveryTM and other digital health interventions used in healthcare systems including the NHS. RB is CEO of Perspectum, which developed CoverscanTM. AB has received research funding from NIHR, British Medical Association, Astra Zeneca, National Institute of Aging and European Union. AB is a Trustee of Long COVID SoS. All other authors report no competing interests. This does not alter our adherence to PLOS ONE policies on sharing data and materials.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>15</Day><Hour>13</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36791116</ArticleId><ArticleId IdType="pmc">PMC9931100</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0272472</ArticleId><ArticleId IdType="pii">PONE-D-22-20207</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV; WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022. Apr;22(4):e102&#x2013;e107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 7 April 2022. 2022.</Citation></Reference><Reference><Citation>Heightman M, Prashar J, Hillman TE, Marks M, Livingston R, Ridsdale HA, et al.. Post-COVID-19 assessment in a specialist clinical service: A 12-month, single-centre, prospective study in 1325 individuals. BMJ Open Respiratory Research. 2021. Nov;8(1):e001041. doi: 10.1136/bmjresp-2021-001041</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjresp-2021-001041</ArticleId><ArticleId IdType="pmc">PMC8587466</ArticleId><ArticleId IdType="pubmed">34764200</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re&#x2019;em Y, et al.. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. eClinicalMedicine. 2021. Aug;38:101019. doi: 10.1016/j.eclinm.2021.101019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelen M, Manoharan L, Elkheir N, Cheng V, Dagens A, Hastie C, et al.. Characterising long COVID: A living systematic review. Vol. 6, BMJ Global Health. 2021. Sep;6(9):e005427. doi: 10.1136/bmjgh-2021-005427</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2021-005427</ArticleId><ArticleId IdType="pmc">PMC8478580</ArticleId><ArticleId IdType="pubmed">34580069</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al.. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020. Aug;584(7821):430&#x2013;436. doi: 10.1038/s41586-020-2521-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2521-4</ArticleId><ArticleId IdType="pmc">PMC7611074</ArticleId><ArticleId IdType="pubmed">32640463</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nature. 2022. Mar;28(3):583&#x2013;590. doi: 10.1038/s41591-022-01689-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01689-3</ArticleId><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021. Jun;594(7862):259&#x2013;264. doi: 10.1038/s41586-021-03553-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03553-9</ArticleId><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>The PHOSP-COVID Collaborative Group. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. Lancet Resp Med. 2022. Aug;10(8):761&#x2013;775. doi: 10.1016/S2213-2600(22)00127-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00127-8</ArticleId><ArticleId IdType="pmc">PMC9034855</ArticleId><ArticleId IdType="pubmed">35472304</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell H, Hotchkiss R, Bradshaw N, Porteous M. Integrated care pathways. Vol. 316, British Medical Journal. 1998. Jan 10;316(7125):133&#x2013;7. doi: 10.1136/bmj.316.7125.133</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.316.7125.133</ArticleId><ArticleId IdType="pmc">PMC2665398</ArticleId><ArticleId IdType="pubmed">9462322</ArticleId></ArticleIdList></Reference><Reference><Citation>Pye A, Roberts SR, Blennerhassett A, Iqbal H, Beenstock J, Iqbal Z. A public health approach to estimating the need for long COVID services. Journal of Public Health. 2021. Oct 14;fdab365. doi: 10.1093/pubmed/fdab365</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/pubmed/fdab365</ArticleId><ArticleId IdType="pubmed">34651183</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson DR, Al-Jabr H, Windle K, Ski CF. Long COVID: Supporting people through the quagmire. Br J Gen Pract. 2021. Nov 25;71(713):561. doi: 10.3399/bjgp21X717917</Citation><ArticleIdList><ArticleId IdType="doi">10.3399/bjgp21X717917</ArticleId><ArticleId IdType="pmc">PMC8686427</ArticleId><ArticleId IdType="pubmed">34824074</ArticleId></ArticleIdList></Reference><Reference><Citation>Nurek M, Rayner C, Freyer A, Taylor S, Jarte L, MacDermott N, et al.. Recommendations for the recognition, diagnosis, and management of long COVID: A Delphi study. British Journal of General Practice. 2021. Oct 28;71(712):e815&#x2013;e825. doi: 10.3399/BJGP.2021.0265</Citation><ArticleIdList><ArticleId IdType="doi">10.3399/BJGP.2021.0265</ArticleId><ArticleId IdType="pmc">PMC8510689</ArticleId><ArticleId IdType="pubmed">34607799</ArticleId></ArticleIdList></Reference><Reference><Citation>NHS England and NHS Improvement. National guidance for post-COVID syndrome assessment clinics. 2021 Apr.</Citation></Reference><Reference><Citation>Dennis A, Wamil M, Alberts J, Oben J, Cuthbertson DJ, Wootton D, et al.. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: A prospective, community-based study. BMJ Open. 2021. Mar 30;11(3):e048391. doi: 10.1136/bmjopen-2020-048391</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-048391</ArticleId><ArticleId IdType="pmc">PMC8727683</ArticleId><ArticleId IdType="pubmed">33785495</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray E, Goodfellow H, Bindman J, Blandford A, Bradbury K, Chaudhry T et al.. Development, deployment and evaluation of digitally enabled, remote, supported rehabilitation for people with long COVID-19 (Living With COVID-19 Recovery): protocol for a mixed-methods study. BMJ Open. 2022. Feb 7;12(2):e057408. doi: 10.1136/bmjopen-2021-057408</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2021-057408</ArticleId><ArticleId IdType="pmc">PMC8822541</ArticleId><ArticleId IdType="pubmed">35131836</ArticleId></ArticleIdList></Reference><Reference><Citation>The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021. Feb 25;384:693&#x2013;704. doi: 10.1056/NEJMoa2021436</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Routen A, O&#x2019;Mahoney L, Ayoubkhani D, Banerjee A, Brightling C, Calvert M, et al.. Understanding and tracking the impact of long COVID in the United Kingdom. Nat Med. 2022. Jan;28(1):11&#x2013;1519. doi: 10.1038/s41591-021-01591-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01591-4</ArticleId><ArticleId IdType="pubmed">34811549</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramasawmy M, Mu Y, Clutterbuck D, Pantelic M, Lip GYH, van der Feltz-Cornelis C et al.. STIMULATE-ICP-CAREINEQUAL (Symptoms, Trajectory, Inequalities and Management: Understanding Long-COVID to Address and Transform Existing Integrated Care Pathways) study protocol: Defining usual care and examining inequalities in Long Covid support PLoS One. 2022. Aug 15;17(8):e0271978. doi: 10.1371/journal.pone.0271978</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0271978</ArticleId><ArticleId IdType="pmc">PMC9377596</ArticleId><ArticleId IdType="pubmed">35969597</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Feltz-Cornelis CM, Sweetman J, Allsopp G, Attree E, Crooks MG, Cuthbertson DJ et al.. STIMULATE-ICP-Delphi (Symptoms, Trajectory, Inequalities and Management: Understanding Long-COVID to Address and Transform Existing Integrated Care Pathways Delphi): Study Protocol. medrxiv. 2022. Apr 7; doi: 10.1371/journal.pone.0277936</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0277936</ArticleId><ArticleId IdType="pmc">PMC9710789</ArticleId><ArticleId IdType="pubmed">36449461</ArticleId></ArticleIdList></Reference><Reference><Citation>Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al.. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research. 2011;20(10). doi: 10.1007/s11136-011-9903-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11136-011-9903-x</ArticleId><ArticleId IdType="pmc">PMC3220807</ArticleId><ArticleId IdType="pubmed">21479777</ArticleId></ArticleIdList></Reference><Reference><Citation>Plummer F, Manea L, Trepel D, McMillan D. Screening for anxiety disorders with the GAD-7 and GAD-2: A systematic review and diagnostic metaanalysis. General Hospital Psychiatry. 2016;39. doi: 10.1016/j.genhosppsych.2015.11.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.genhosppsych.2015.11.005</ArticleId><ArticleId IdType="pubmed">26719105</ArticleId></ArticleIdList></Reference><Reference><Citation>He C, Levis B, Riehm KE, Saadat N, Levis AW, Azar M, et al.. The Accuracy of the Patient Health Questionnaire-9 Algorithm for Screening to Detect Major Depression: An Individual Participant Data Meta-Analysis. Psychotherapy and Psychosomatics. 2020;89(1). doi: 10.1159/000502294</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000502294</ArticleId><ArticleId IdType="pmc">PMC6960351</ArticleId><ArticleId IdType="pubmed">31593971</ArticleId></ArticleIdList></Reference><Reference><Citation>Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7). doi: 10.1136/thx.54.7.581</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thx.54.7.581</ArticleId><ArticleId IdType="pmc">PMC1745516</ArticleId><ArticleId IdType="pubmed">10377201</ArticleId></ArticleIdList></Reference><Reference><Citation>Rashidian H, Subramaniapillai M, Park C, Lipsitz O, Zuckerman H, Teopiz K, et al.. Insulin resistance is associated with deficits in hedonic, self-reported cognitive, and psychosocial functional response to antidepressant treatment in individuals with major depressive disorder. Journal of Affective Disorders. 2021;282. doi: 10.1016/j.jad.2020.12.074</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2020.12.074</ArticleId><ArticleId IdType="pubmed">33422821</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahra D, Qureshi A, Henley W, Taylor R, Quinn C, Pooler J, et al.. The work and social adjustment scale: Reliability, sensitivity and value. International Journal of Psychiatry in Clinical Practice. 2014;18(2). doi: 10.3109/13651501.2014.894072</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/13651501.2014.894072</ArticleId><ArticleId IdType="pubmed">24527886</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouwmans C, Krol M, Severens H, Koopmanschap M, Brouwer W, Roijen LH van. The iMTA Productivity Cost Questionnaire: A Standardized Instrument for Measuring and Valuing Health-Related Productivity Losses. Value in Health. 2015;18(6). doi: 10.1016/j.jval.2015.05.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2015.05.009</ArticleId><ArticleId IdType="pubmed">26409601</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkinson C, Layte R. Development and testing of the UK SF-12. Journal of Health Services Research and Policy. 1997;2(1).</Citation><ArticleIdList><ArticleId IdType="pubmed">10180648</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutubuki EN, van der Maaden T, Leung KY, Wong A, Tulen AD, de Bruijn S, et al.. Prevalence and determinants of persistent symptoms after infection with SARS-CoV-2: Protocol for an observational cohort study (LongCOVID-study). medRxiv. 2022; doi: 10.1136/bmjopen-2022-062439</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2022-062439</ArticleId><ArticleId IdType="pmc">PMC9251892</ArticleId><ArticleId IdType="pubmed">35777877</ArticleId></ArticleIdList></Reference><Reference><Citation>Broadbent DE, Cooper PF, FitzGerald P, Parkes KR. The cognitive failures questionnaire (CFQ) and its correlates. British Journal of Clinical Psychology. 1982;21(1). doi: 10.1111/j.2044-8260.1982.tb01421.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.2044-8260.1982.tb01421.x</ArticleId><ArticleId IdType="pubmed">7126941</ArticleId></ArticleIdList></Reference><Reference><Citation>Munblit D, Nicholson T, Akrami A, Apfelbacher C, Chen J, de Groote W, et al.. A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study. The Lancet Respiratory Medicine. 2022. Jul;10(7):715&#x2013;24. doi: 10.1016/S2213-2600(22)00169-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00169-2</ArticleId><ArticleId IdType="pmc">PMC9197249</ArticleId><ArticleId IdType="pubmed">35714658</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomized trials. Vol. 152, Annals of Internal Medicine. 2010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3116666</ArticleId><ArticleId IdType="pubmed">21686296</ArticleId></ArticleIdList></Reference><Reference><Citation>International Conference on Harmonisation (ICH). ICH Harmonised Tripartite Guideline E9: Statistical Principles for Clinical Trials. Statistics in Medicine. 1999;18(15).</Citation><ArticleIdList><ArticleId IdType="pubmed">10532877</ArticleId></ArticleIdList></Reference><Reference><Citation>de Kleijn WPE, de Vries J, Wijnen PAHM, Drent M. Minimal (clinically) important differences for the Fatigue Assessment Scale in sarcoidosis. Respiratory Medicine. 2011;105(9). doi: 10.1016/j.rmed.2011.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2011.05.004</ArticleId><ArticleId IdType="pubmed">21700440</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan AW, Tetzlaff JM, G&#xf8;tzsche PC, Altman DG, Mann H, Berlin JA, et al.. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346. doi: 10.1136/bmj.e7586</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.e7586</ArticleId><ArticleId IdType="pmc">PMC3541470</ArticleId><ArticleId IdType="pubmed">23303884</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>